{"id":936968,"date":"2026-02-13T10:28:51","date_gmt":"2026-02-13T15:28:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/"},"modified":"2026-02-13T10:28:51","modified_gmt":"2026-02-13T15:28:51","slug":"moleculin-launches-ceo-corner-platform-to-share-strategic-insights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/","title":{"rendered":"Moleculin Launches CEO Corner Platform to Share Strategic Insights"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress<\/i>\n      <\/p>\n<p align=\"center\">\n        <i>Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos<\/i>\n      <\/p>\n<p align=\"center\">\n        <i>Access the Moleculin CEO Corner <\/i><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VAUEms12vEQVngVEl8W35rP19Xv9oNcHPYyUOj_tQyrHZIoyl6wytGt7jCRtZ2NzUiZpdtWS5LgAYlYPdpA6Ig==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <i>here<\/i><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">\n        <b>HOUSTON, Feb.  13, 2026  (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc.<\/b>, (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company\u2019s corporate developments, clinical progress and strategic initiatives.<\/p>\n<p align=\"justify\">\u201cTransparency and timely communication are central to building trust with our investors,\u201d commented Klemp. \u201cOur CEO Corner gives us the opportunity to go beyond standard press releases, providing deeper context on our pipeline programs, clinical milestones and business strategy. We are focused on advancing our lead programs, including our ongoing clinical trials, and delivering long-term value for our shareholders.\u201d<\/p>\n<p align=\"justify\" \/>\n<p align=\"justify\">Access the CEO Corner on the Company\u2019s website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VAUEms12vEQVngVEl8W35jlDWHPMia_FRDi6eQnjIPPtWCUoNiT_Plj4XVc5Wim2QQzuNqcybe_4sRIRXNAqkw==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <b>About Moleculin Biotech, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company\u2019s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.<\/p>\n<p align=\"justify\">The Company has begun the MIRACLE (Moleculin\u00a0R\/R AML\u00a0AnnAraC\u00a0Clinical\u00a0Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as \u201cAra-C\u201d) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n<p align=\"justify\">Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.<\/p>\n<p align=\"justify\">For more information about the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-NwaQCIs_11ffXpz2-rHcODPZ5LYJ5hEucwW20N3XUad6fVzSyjf0V0QuRTSOVES9yq5EfsCPj_s2BFf0XiKsR2T4HANdNvjkz5wOU2klagoyfkvNk_QmC1WxNyuIv1qHZK1FH5wiFbjJhOTU98ujJlJwauOa1DgrBNfzdTBGkDK5x84zntubPA9_OJF1NggTDK2jItXd88q41Ke7gG1BcCnS5vokJT0m7gMMbothvvb8eaIw7shPQg2tyTVTjnXOyia3L7zqF2Va2FM0lNpBw==\" rel=\"nofollow\" target=\"_blank\">www.moleculin.com<\/a>\u00a0and connect on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=luN6C0hufkEF_joeYCT2AP99cqRL5l4Av2LUJ1RvfMcJJLl8oTdjQI5Ay3mNI6esWrUmTUCKMqUM5LCJNPQ5vOopv5cnbiHCgzzD3km4eCHGRIrv7nUPQkoQQLgz8Dj7UMPMd598y8-ej44dZ2ZuntdvrYPie4WmV5_IwyhDMdtSxOuZjG_u7HqEKSQYgb-DUs0X4r7R0Xcoxs5KR_COzg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cg1-kDQjHJvjJi2KbOfHy_do4_CT_qTmVCZElQlc4hprhcIb1G1yHrVl_9pa5S9CN0-7TX3xTjfIoV6Zj5v4Ii1S-oByE_2P0i6N1KC_AY7gr54246aSkxukZ_LgG_7SuggSSxVVCXq24myL9XZ3Zz9Lgql3zsp3Oz7IC1ugdS5sQzc7eeezJyXRWEW82PPS_PqiqyIOqZR1Hbbrq5XO7iCiEVaqHuLbxtLndYsMzqldz55SUKuLZjwBFCw23FMv--HmG1v3aJb03qWTLPHj3g==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q_MMT5S0Qn0lSxAlxIlIu063Oe6-vEbSzA_3Qc6MIZECupKqu1DtY-1lYh_6UlXIbicAjLP1TJ-pZ8GD_LjRc55lspfl5ZmUsQIc6rviU8S91k4dkEo2MBIEl6Jex-j2GpohVDJpNfNwaXjF05ChBFCiYfnG525okV-X3QN56LwH4viiZl0D2jpsNE9-NnRpdOE7aw_fjZP9KFtEj1IFoiwKi6dMOUiPN_BYQCdUMglrNp-m1Scl2WbRU2VfMSK0\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding the continued recruitment, treatment, and receipt of the unblinded data for the first 45 subjects of the MIRACLE clinical trial as described. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company\u2019s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including \u2018believes,\u2019 \u2018estimates,\u2019 \u2018anticipates,\u2019 \u2018expects,\u2019 \u2018plans,\u2019 \u2018projects,\u2019 \u2018intends,\u2019 \u2018potential,\u2019 \u2018may,\u2019 \u2018could,\u2019 \u2018might,\u2019 \u2018will,\u2019 \u2018should,\u2019 \u2018approximately\u2019 or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. \u201cRisk Factors\u201d in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KhbbEWNXWCACAeqVA_3lP9OwnUKr3uTe5aY59C-UjIHrlJTWcRQQ2_XshJki4WEWAalRgpwYdEXchh1_AUX7iA==\" rel=\"nofollow\" target=\"_blank\">MBRX@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTQzMDAyYjAtNTEyMi00ZTNjLTk1MmYtNTNjNzQ3OTgzYmI3LTUwMDEzMzYwNy0yMDI2LTAyLTEzLWVu\/tiny\/Moleculin-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company\u2019s corporate developments, clinical progress and strategic initiatives. \u201cTransparency and timely communication are central to building trust with our investors,\u201d commented Klemp. \u201cOur CEO Corner gives us the opportunity to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moleculin Launches CEO Corner Platform to Share Strategic Insights&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936968","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company\u2019s corporate developments, clinical progress and strategic initiatives. \u201cTransparency and timely communication are central to building trust with our investors,\u201d commented Klemp. \u201cOur CEO Corner gives us the opportunity to &hellip; Continue reading &quot;Moleculin Launches CEO Corner Platform to Share Strategic Insights&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T15:28:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin Launches CEO Corner Platform to Share Strategic Insights\",\"datePublished\":\"2026-02-13T15:28:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/\"},\"wordCount\":800,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/\",\"name\":\"Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\",\"datePublished\":\"2026-02-13T15:28:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin Launches CEO Corner Platform to Share Strategic Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk","og_description":"CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company\u2019s corporate developments, clinical progress and strategic initiatives. \u201cTransparency and timely communication are central to building trust with our investors,\u201d commented Klemp. \u201cOur CEO Corner gives us the opportunity to &hellip; Continue reading \"Moleculin Launches CEO Corner Platform to Share Strategic Insights\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T15:28:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin Launches CEO Corner Platform to Share Strategic Insights","datePublished":"2026-02-13T15:28:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/"},"wordCount":800,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/","name":"Moleculin Launches CEO Corner Platform to Share Strategic Insights - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==","datePublished":"2026-02-13T15:28:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDIzNCM3NDI0ODU1IzUwMDEzMzYwNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-launches-ceo-corner-platform-to-share-strategic-insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin Launches CEO Corner Platform to Share Strategic Insights"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936968"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936968\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}